Page 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 FORM 10 - K ( Mark One ) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ΤΟ Switzerland ( State or other jurisdiction of incorporation or organization ) Baarerstrasse 14 CRISPR THERAPEUTICS AG ( Exact name of Registrant as specified in its Charter ) 6300 Zug , Switzerland ( Address of principal executive offices ) Securities registered pursuant to Section 12 ( b ) of the Act : Commission File Number 001-37923 Not Applicable ( Zip Code ) Registrant's telephone number , including area code : +41 ( 0 ) 41 561 32 77 Title of each class Common Shares , nominal value CHF 0.03 0 Not Applicable ( I.R.S. Employer Identification No. ) Trading Symbol ( s ) CRSP Name of each exchange on which registered The Nasdaq Global Market Securities registered pursuant to Section 12 ( g ) of the Act : None Indicate by check mark if the Registrant is a well - known seasoned issuer , as defined in Rule 405 of the Securities Act . YES NO Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15 ( d ) of the Act . YES NO Indicate by check mark whether the Registrant : ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the Registrant was required to file such reports ) , and ( 2 ) has been subject to such filing requirements for the past 90 days . YES NO Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S - T ( §232.405 of this chapter ) during the preceding 12 months ( or for such shorter period that the Registrant was required to submit such files ) . YES NO □ Indicate by check mark whether the Registrant is a large accelerated filer , an accelerated filer , a non - accelerated filer , smaller reporting company , or an emerging growth company . See the definitions of " large accelerated filer , " " accelerated filer , " " smaller reporting company , " and " emerging growth company " in Rule 12b - 2 of the Exchange Act . Large accelerated filer Non - accelerated filer Accelerated filer Smaller reporting company Emerging growth company If an emerging growth company , indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 ( a ) of the Exchange Act . Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404 ( b ) of the Sarbanes - Oxley Act ( 15 U.S.C. 7262 ( b ) ) by the registered public accounting firm that prepared or issued its audit report . Indicate by check mark whether the Registrant is a shell company ( as defined in Rule 12b - 2 of the Exchange Act ) . YES NO The aggregate market value of the common shares held by non - affiliates of the Registrant was approximately $ 4.5 billion , based on the closing price on the Nasdaq Global Market of the Registrant's common shares on June 30 , 2020 ( the last trading day of the Registrant's second fiscal quarter of 2020 ) . The number of the Registrant's common shares outstanding as of February 11 , 2021 was 75,428,927 . DOCUMENTS INCORPORATED BY REFERENCE 0 Portions of the Registrant's Definitive Proxy Statement relating to the 2021 Annual General Meeting of Shareholders , which the Registrant intends to file with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the Registrant's fiscal year ended December 31 , 2020 , are incorporated by reference into Part III of this Report .